JW Lifescience Corporation

KOSE:A234080 Stock Report

Market Cap: ₩177.1b

JW Lifescience Dividends and Buybacks

Dividend criteria checks 4/6

JW Lifescience is a dividend paying company with a current yield of 4.4% that is well covered by earnings. Next payment date is on 28th April, 2025 with an ex-dividend date of 27th December, 2024.

Key information

4.4%

Dividend yield

n/a

Buyback Yield

Total Shareholder Yieldn/a
Future Dividend Yieldn/a
Dividend Growth16.1%
Next dividend pay date28 Apr 25
Ex dividend date27 Dec 24
Dividend per share₩500.000
Payout ratio27%

Recent dividend and buyback updates

Is It Smart To Buy JW Lifescience Corporation (KRX:234080) Before It Goes Ex-Dividend?

Dec 23
Is It Smart To Buy JW Lifescience Corporation (KRX:234080) Before It Goes Ex-Dividend?

Recent updates

Solid Earnings Reflect JW Lifescience's (KRX:234080) Strength As A Business

Nov 24
Solid Earnings Reflect JW Lifescience's (KRX:234080) Strength As A Business

We Think JW Lifescience (KRX:234080) Can Manage Its Debt With Ease

Apr 20
We Think JW Lifescience (KRX:234080) Can Manage Its Debt With Ease

Introducing JW Lifescience (KRX:234080), A Stock That Climbed 36% In The Last Year

Mar 11
Introducing JW Lifescience (KRX:234080), A Stock That Climbed 36% In The Last Year

What Type Of Shareholders Make Up JW Lifescience Corporation's (KRX:234080) Share Registry?

Feb 21
What Type Of Shareholders Make Up JW Lifescience Corporation's (KRX:234080) Share Registry?

Is JW Lifescience Corporation (KRX:234080) A Smart Pick For Income Investors?

Feb 02
Is JW Lifescience Corporation (KRX:234080) A Smart Pick For Income Investors?

We Think JW Lifescience (KRX:234080) Can Manage Its Debt With Ease

Jan 12
We Think JW Lifescience (KRX:234080) Can Manage Its Debt With Ease

Is It Smart To Buy JW Lifescience Corporation (KRX:234080) Before It Goes Ex-Dividend?

Dec 23
Is It Smart To Buy JW Lifescience Corporation (KRX:234080) Before It Goes Ex-Dividend?

Is JW Lifescience Corporation's (KRX:234080) Recent Performance Tethered To Its Attractive Financial Prospects?

Dec 23
Is JW Lifescience Corporation's (KRX:234080) Recent Performance Tethered To Its Attractive Financial Prospects?

How Much Did JW Lifescience's(KRX:234080) Shareholders Earn From Share Price Movements Over The Last Three Years?

Nov 27
How Much Did JW Lifescience's(KRX:234080) Shareholders Earn From Share Price Movements Over The Last Three Years?

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Whilst dividend payments have been stable, A234080 has been paying a dividend for less than 10 years.

Growing Dividend: A234080 has only been paying a dividend for 7 years, and since then payments have not increased.


Dividend Yield vs Market

JW Lifescience Dividend Yield vs Market
How does A234080 dividend yield compare to the market?
SegmentDividend Yield
Company (A234080)4.4%
Market Bottom 25% (KR)1.2%
Market Top 25% (KR)3.9%
Industry Average (Pharmaceuticals)1.1%
Analyst forecast (A234080) (up to 3 years)n/a

Notable Dividend: A234080's dividend (4.4%) is higher than the bottom 25% of dividend payers in the KR market (1.24%).

High Dividend: A234080's dividend (4.4%) is in the top 25% of dividend payers in the KR market (3.91%)


Earnings Payout to Shareholders

Earnings Coverage: With its reasonably low payout ratio (26.9%), A234080's dividend payments are well covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: With its low cash payout ratio (16.3%), A234080's dividend payments are well covered by cash flows.


Discover strong dividend paying companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 21:23
End of Day Share Price 2024/12/26 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

JW Lifescience Corporation is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Hyung Soo KimCape Investment & Securities Co., Ltd.
Tae Young LeeKB Securities Co., Ltd.
Changmin YoonShinhan Investment Corp.